336 related articles for article (PubMed ID: 30798282)
21. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
[TBL] [Abstract][Full Text] [Related]
22. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score.
Travaglino F; De Berardinis B; Magrini L; Bongiovanni C; Candelli M; Silveri NG; Legramante J; Galante A; Salerno G; Cardelli P; Di Somma S
BMC Infect Dis; 2012 Aug; 12():184. PubMed ID: 22874067
[TBL] [Abstract][Full Text] [Related]
23. Plasma levels of mid-regional pro-adrenomedullin in sepsis are associated with risk of death.
Valenzuela-Sánchez F; Valenzuela-Méndez B; Bohollo de Austria R; Rodríguez-Gutiérrez JF; Estella-García Á; Fernández-Ruiz L; González-García MÁ; Rello J
Minerva Anestesiol; 2019 Apr; 85(4):366-375. PubMed ID: 30207133
[TBL] [Abstract][Full Text] [Related]
24. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
[TBL] [Abstract][Full Text] [Related]
25. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
27. Does mid-regional pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study.
Haag E; Gregoriano C; Molitor A; Kloter M; Kutz A; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 May; 59(6):1165-1176. PubMed ID: 33554514
[TBL] [Abstract][Full Text] [Related]
28. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
[TBL] [Abstract][Full Text] [Related]
29. MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.
Heining L; Giesa C; Ewig S
Lung; 2016 Apr; 194(2):185-91. PubMed ID: 26748496
[TBL] [Abstract][Full Text] [Related]
30. Stable-State Midrange Proadrenomedullin Is Associated With Severe Exacerbations in COPD.
Citgez E; Zuur-Telgen M; van der Palen J; van der Valk P; Stolz D; Brusse-Keizer M
Chest; 2018 Jul; 154(1):51-57. PubMed ID: 29475034
[TBL] [Abstract][Full Text] [Related]
31. The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study.
Saeed K; Wilson DC; Bloos F; Schuetz P; van der Does Y; Melander O; Hausfater P; Legramante JM; Claessens YE; Amin D; Rosenqvist M; White G; Mueller B; Limper M; Callejo CC; Brandi A; Macchi MA; Cortes N; Kutz A; Patka P; Yañez MC; Bernardini S; Beau N; Dryden M; van Gorp ECM; Minieri M; Chan L; Rood PPM; Del Castillo JG
Crit Care; 2019 Feb; 23(1):40. PubMed ID: 30736862
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.
Montrucchio G; Sales G; Balzani E; Lombardo D; Giaccone A; Cantù G; D'Antonio G; Rumbolo F; Corcione S; Simonetti U; Bonetto C; Zanierato M; Fanelli V; Filippini C; Mengozzi G; Brazzi L
Front Med (Lausanne); 2023; 10():1122367. PubMed ID: 37035317
[TBL] [Abstract][Full Text] [Related]
33. Stress markers predict mortality in patients with nonspecific complaints presenting to the emergency department and may be a useful risk stratification tool to support disposition planning.
Nickel CH; Messmer AS; Geigy N; Misch F; Mueller B; Dusemund F; Hertel S; Hartmann O; Giersdorf S; Bingisser R
Acad Emerg Med; 2013 Jul; 20(7):670-9. PubMed ID: 23859580
[TBL] [Abstract][Full Text] [Related]
34. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
[TBL] [Abstract][Full Text] [Related]
35. MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy.
Falkentoft AC; Rørth R; Iversen K; Høfsten DE; Kelbæk H; Holmvang L; Frydland M; Schoos MM; Helqvist S; Axelsson A; Clemmensen P; Jørgensen E; Saunamäki K; Tilsted HH; Pedersen F; Torp-Pedersen C; Kofoed KF; Goetze JP; Engstrøm T; Køber L
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29776961
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
[TBL] [Abstract][Full Text] [Related]
37. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
[TBL] [Abstract][Full Text] [Related]
39. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center.
Benedetti I; Spinelli D; Callegari T; Bonometti R; Molinaro E; Novara E; Cassinari M; Frino C; Guaschino R; Boverio R; Lauritano EC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1743-1751. PubMed ID: 33629344
[TBL] [Abstract][Full Text] [Related]
40. Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study.
Odermatt J; Meili M; Hersberger L; Bolliger R; Christ-Crain M; Briel M; Bucher HC; Mueller B; Schuetz P
BMC Cardiovasc Disord; 2017 Jul; 17(1):178. PubMed ID: 28676115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
